In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 4, 1999, Pages 981-989

  Miller, Richard A ^a   Woodburn, Kathryn ^a   Fan, Qing ^a   Renschler, Markus F ^a   Sessler, Jonathan L ^b   Koutcher, Jason A ^c  

^a PHARMACYCLICS INC   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gadolinium; Preclinical; Radiation; Sensitizer; Texaphyrin

Indexed keywords

CADMIUM; EUROPIUM; GADOLINIUM CHELATE; GADOLINIUM TEXAPHYRIN; LUTETIUM; METAL COMPLEX; PORPHYRIN DERIVATIVE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; YTTRIUM;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIOSENSITIZATION; TUMOR GROWTH; TUMOR MODEL;

EID: 0032747288     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00274-6     Document Type: Article

References (37)

1. Coleman C.N. Radiation and chemotherapy sensitizers and protectors. Chabner B.A., Long D.L. Cancer chemotherapy and biotherapy. 1996;553-583 Lippincott-Raven, Philadelphia.
2. Coleman C.N., Mitchell J.B. Clinical radiosensitization Why it does and does not work . J Clin Onc. 17:1999;1-3.
3. Wasserman T.H., Phillips T.L., Johnson R.J. Initial clinical and pharmacologic evaluation of misonidazole (R1-07-0582) a hypoxic cell sensitizer. Int J Radiat Oncol Biol Phys. 5:1979;775.
4. Wasserman T.H., Stetz J.A., Phillips T.L. Radiation Therapy Group clinical trials with misonidazole. Cancer. 47:1981;2382.
5. Kinsella T.J., Mitchell J.B., Russo A. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys. 10:1984;69-76.
6. Wasserman T.H., Chapman J.D., Coleman C.N., et al. Chemical modifiers of radiation. Peres C.A., Brady L.W. Principles and practice of radiation oncology. 1998;685-704 Lippincott-Raven, Philadelphia.
7. Brown J.M. SR4223 (Tirapazamine) A new anticancer drug exploiting hypoxia in solid tumours . Br J Cancer. 67:1993;1163-1170.
8. Bristow R.G., Hardy P.A., Hill R.P. Comparison between in vitro radiosensitivity and in vivo radioresponse of murine tumor cell lines I Parameters of in vitro radiosensitivity and endogenous cellular glutathione levels . Int J Radiat Oncol Biol Phys. 18:1990;133-145.
9. Bristow R.G., Hill R.P. Comparison between in vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines II In vivo radioresponse following fractionated treatment and in vitro/in vivo correlations . Int J Radiat Oncol Biol Phys. 18:1990;331-345.
10. Baumann M., DuBois W., Pu A., et al. Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. Int J Radiat Oncol Biol Phys. 23:1992;803-809.
11. Taghian A., DuBois W., Budach W., et al. In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 32:1995;99-104.
12. Taghian A., Ramsay J., Allalunis-Turner J., et al. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 25:1993;243-249.
13. Sessler J.L., Hemmi G., Mody T.D., et al. Texaphyrins Synthesis and applications . Acc Chem Res. 27:1994;43-50.
14. Sessler J.L., Mody T.D., Hemmi G.W., et al. Gadolinium (III) texaphyrin A novel MRI contrast agent . Am Chem Soc. 115:1993;10368-10369.
15. Young S.W., Fan Q., Harriman A., Hao Y., Miller R.A., et al. Gadolinium(III) texaphyrin A tumor selective radiation sensitizer that is detectable by MRI . Proc Natl Acad Sci. 93:1996;6610-6615.
16. Viala J, Vanel D, Moingan P; et al. A phase IB/II multi-dose trial of Gadolinium-texaphyrin (Gd-Tex), a radiation sensitizer that is detectable by MR imaging: Preliminary results on brain metastases. Radiology. In press.
17. Rosenthal D.E., Nuremberg P., Becerra C.R., et al. A Phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res. 5:1999;739-745.
18. Timmerman B., Carde P., Koprowski C., et al. Phase IB/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases Final results . Int J Radiat Oncol Biol Phys. 42:1998;198. (Abstr).
19. Carde P., Timmerman B., Koprowski C., et al. Gadolinium-Texaphyrin (Gd-Tex) radiation sensitizer Improved survival in a Phase IB/II trial in patients with brain metastases . Proc Am Soc Clin Onc. 17:1998;379a. (Abstr).
20. Young S.W., Woodburn K.W., Wright M., et al. Lutetium texaphyrin (PCI-0123) A near-infrared, water-soluble photosensitizer . Photochem Photobiol. 63:1996;892-897.
21. Sessler J.L., Mody T.M., Hemmi G.W., et al. Synthesis and structural characterization of lanthanide(III) texaphyrins. Inorg Chem. 32:1993;3175-3187.
22. Rockwell S.C., Kallman R.F., Fajardo L.F. Characteristics of a serially transplanted mouse mammary tumor and its tissue culture adapted derivative. J Natl Cancer Inst. 49:1972;735-749.
23. Pavelic Z.P., Porter C.W., Allen L.M., et al. Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res. 38:1978;1533-1538.
24. Stone H.B., Sinesi M.S. Testing of new hypoxic cell sensitizers in vivo. Radiat Res. 91:1982;186-198.
25. Koutcher J.A., Alfieri A.A., Devitt M.L., et al. Quantitative changes in tumor metabolism, partial pressure of oxygen and radiobiological oxygenation status postradiation. Cancer Res. 52:1992;4620-4627.
26. Rockwell S., Kallman R.F. Cellular radiosensitivity and tumor response in the EMT6 tumor cell system. Radiat Res. 53:1973;281-294.
27. Brown J.M., Yu N.Y. Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses A preliminary report . Int J Radiat Oncol Biol Phys. 10:1984;1207-1212.
28. Sessler J.L., Tvermoes N.A., Guldi D.M., et al. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble texaphyrins. J Phys Chem. 103:1999;787-794.
29. Zamzami N., Marchetti P., Castedo M., et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 182:1995;367-377.
30. Papa S., Skulachev V.P. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Biochem. 174:1997;305-319.
31. Waldman T., Zhang Y., Dillehay L., et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 3:1997;1034-1036.
32. Fingar V.H., Haydon P.S., Taber S.W., et al. Assessment of selected damage to tumor vasculature after PDT. Photochem Photobiol. 67S:1998;25S. (Abstr).
33. Mauceri H.J., Hanna N.N., Beckett M.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394:1998;287-291.
34. O'Hara J.A., Douple E.V., Abrams M.J., et al. Potentiation of radiation-induced cell kill by synthetic metalloporphyrins. Int J Radiat Oncol Biol Phys. 16:1989;1049-1052.
35. James B.R., Meng G.G., Posakony J.J., et al. Porphyrins and metaloporphyrins Potential hypoxic agents . Metal-Based Drugs. 3:1996;85-89.
36. Miller E.M., Fowler J.F., Kinsella T.J. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. Rad Res. 131:1992;81-89.
37. Young S.W., Fan Q., Harriman A., et al. Gadolinium(III) texaphyrin A tumor selective radiation sensitizer that is detectable by MRI . Proc Natl Acad Sci. 96:1999;291. (Correction).